Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study

Overview of attention for article published in Journal of Translational Medicine, June 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 16 X posts from 12 X users, with an upper bound of 26,476 followers.

RT @AbbateAntonio: Another piece of the puzzle @VCUHealthHeart @UVACVRC @CardioUva

RT @gbiondizoccai: Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): randomized, double bl…

RT @AbbateAntonio: Another piece of the puzzle @VCUHealthHeart @UVACVRC @CardioUva

RT @gbiondizoccai: Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): randomized, double bl…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 12 additional X posts.